Looking beyond EGFR targeting strategies for GBM treatment, genomic and expression analysis of GBMs has highlighted several onco-dependent kinase targets for potential therapeutic intervention, including the tyrosine kinases Met, FGFR, and Axl [80]. This evidence concerns the gene MET and glioblastoma.